The Relative Strength (RS) Rating for Amgen stock entered a new percentile Monday, with a rise from 75 to 81.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's proprietary RS Rating measures technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of above 80 as they launch their biggest runs.
Looking For Winning Stocks? Try This Simple Routine
Is Amgen Stock A Buy?
Amgen stock is working on a cup with handle with a 268.24 entry. See if it can clear the breakout price in heavy trade. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
Earnings grew 8% last quarter, up from -6% in the prior report. Revenue also increased, from -2% to 6%.
Amgen stock holds the No. 13 rank among its peers in the Medical-Biomed/Biotech industry group. Horizon Therapeutics and Kiniksa Pharmaceuticals are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
